AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 81 min read$CNTB

HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target

HC Wainwright & Co. reiterated a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying 641% upside from the last close. The firm cited positive clinical data for rademikibart, showing significant improvements in asthma and COPD treatments, and external validation from NEJM publication of tozorakimab data. Recent analyst price targets for the company range from $5 to $7.

Original reporting
tradingview.com
Published Oct 8, 2026, 10:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$CNTBBullishMed
01

Why it matters

Analyst upgrade reflects confidence in trial results and potential market opportunity.

02

Market read

New rating and price target provide a short-term trading catalyst for CNTB.

03

What to watch

Regulatory timeline and competitive landscape could delay commercialization.

Relevance 6/10Novelty 6/10Timing: today

Background

Connect Biopharma recently reported positive Phase 2 data for rademikibart in asthma and COPD.

Company-level read

Ticker impact

$CNTBBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on Connect Biopharma Holdings with a $7 price target, implying a 641% upside.

Expected impact

likely upward pressure as investors price in the new target.

Evidence & confidence

The fresh Buy rating and aggressive target provide a clear catalyst for buying pressure.

Market effects

Sector

Positive sentiment may spill over to other biotech stocks with similar pipelines.

Regional

Limited to U.S. biotech sector.

Global

Minor global impact, confined to niche biotech investors.

Counterpoint

What could challenge this read

The target may be overly optimistic given early-stage trial data.

Key entities

  • company
    Connect Biopharma Holdings

    Biotech firm developing rademikibart for respiratory diseases.

  • analyst_firm
    HC Wainwright & Co.

    Equity research firm that issued the Buy rating.

Read at source← All news

Related articles

SEP 30
$CNTBHighAI 9/10

Why is Connect Biopharma stock surging today?

Connect Biopharma (CNTB) stock rose 17.4% to $1.165 after positive Phase 2 trial results for its COPD treatment, rademikibart. The drug showed significant efficacy, reducing treatment failure rates and exacerbations. BTIG lowered its price target to $5.00 but maintained a Buy rating. Analysts generally remain positive, with a consensus price target of $6.14. The company plans to discuss Phase 3 development with the FDA. The broader market also gained due to softer inflation data.

investing.com2 min
SEP 30
$CNTBHighAI 8/10

BTIG cuts Connect Biopharma stock price target on trial timeline

BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.

investing.com2 min
SEP 30
$CNTBHighAI 9/10

Connect Biopharma stock jumps on positive COPD trial data

Connect Biopharma (NASDAQ:CNTB) shares rose 25% after reporting positive Phase 2 trial results for rademikibart, a drug candidate for COPD. The study showed significant reductions in treatment failure, exacerbations, and hospitalizations compared to placebo. The company plans to discuss a Phase 3 program with the FDA and may receive up to $99 million in milestone payments from Simcere Pharmaceutical.

investing.com2 min